IM Cannabis (NASDAQ:IMCC – Get Free Report) is set to release its earnings data before the market opens on Thursday, November 14th. Analysts expect IM Cannabis to post earnings of ($1.03) per share for the quarter.
IM Cannabis (NASDAQ:IMCC – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.67. The business had revenue of $10.78 million during the quarter, compared to the consensus estimate of $9.62 million. IM Cannabis had a negative net margin of 26.46% and a negative return on equity of 97.26%. On average, analysts expect IM Cannabis to post $-6 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
IM Cannabis Price Performance
IMCC stock opened at $2.35 on Wednesday. IM Cannabis has a 52-week low of $1.13 and a 52-week high of $8.10. The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.07. The stock has a market cap of $5.24 million, a price-to-earnings ratio of -0.58 and a beta of 0.45. The business has a fifty day moving average of $2.19 and a two-hundred day moving average of $2.82.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands.
Featured Articles
- Five stocks we like better than IM Cannabis
- Compound Interest and Why It Matters When Investing
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- What Does a Stock Split Mean?
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Consumer Discretionary Stocks Explained
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.